Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy
BackgroundTesticular sex cord stromal tumours (TSCSTs) are rare, with few studies focusing on the metastatic TSCST prognosis. The value of treatments, including radical orchiectomy (RO) and retroperitoneal lymph node dissection (RPLND), in preventing metastasis is controversial. Additionally, metast...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.720359/full |
| _version_ | 1818943356479209472 |
|---|---|
| author | Bingqing Shang Chuanzhen Cao Weixing Jiang Hongzhe Shi Xingang Bi Chengxu Cui Jianzhong Shou Shan Zheng Jin Zhang Aiping Zhou Changling Li Jianhui Ma |
| author_facet | Bingqing Shang Chuanzhen Cao Weixing Jiang Hongzhe Shi Xingang Bi Chengxu Cui Jianzhong Shou Shan Zheng Jin Zhang Aiping Zhou Changling Li Jianhui Ma |
| author_sort | Bingqing Shang |
| collection | DOAJ |
| description | BackgroundTesticular sex cord stromal tumours (TSCSTs) are rare, with few studies focusing on the metastatic TSCST prognosis. The value of treatments, including radical orchiectomy (RO) and retroperitoneal lymph node dissection (RPLND), in preventing metastasis is controversial. Additionally, metastatic TSCSTs are resistant to chemotherapy. We aimed to assess the effectiveness and safety of immunotherapy in metastatic TSCSTs after first-line chemotherapy.MethodsWe retrospectively screened patients with testicular tumours undergoing testis surgery between January 2005 and January 2019. Patients with TSCSTs who had undergone testis-sparing surgery (TSS) or RO were identified. The malignant type was defined as metastasis confirmed by pathology. Treatment responses, progression-free survival (PFS), overall survival (OS) and safety were analysed.ResultsAmong the 494 testicular tumour patients who received TSS or RO, 11 (2.2%) patients with histologically proven TSCSTs were identified. At the last follow-up, 7 patients survived without tumours, and 4 patients developed metastasis and received first-line cisplatin-based chemotherapy, with 1 of them achieving an objective response. Their PFS times were 1.5, 2.2, 9.0, and 17.0 months, respectively. Two patients received immune checkpoint inhibitors (ICIs) after developing chemotherapy resistance and achieved a partial response up to the last follow-up; one of them experienced Grade 1 adverse events, and the other experienced Grade 2 adverse events during immunotherapy. The median OS time of the 4 patients with metastatic TSCSTs was 32 months.ConclusionsTSCSTs are rare, and most are benign with a good prognosis. ICIs represent a promising option for improving clinical outcomes in metastatic TSCSTs. |
| first_indexed | 2024-12-20T07:26:02Z |
| format | Article |
| id | doaj.art-d8e3c112ba6649a793db5544cdd73276 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T07:26:02Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d8e3c112ba6649a793db5544cdd732762022-12-21T19:48:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-01-011210.3389/fimmu.2021.720359720359Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line ChemotherapyBingqing Shang0Chuanzhen Cao1Weixing Jiang2Hongzhe Shi3Xingang Bi4Chengxu Cui5Jianzhong Shou6Shan Zheng7Jin Zhang8Aiping Zhou9Changling Li10Jianhui Ma11Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBackgroundTesticular sex cord stromal tumours (TSCSTs) are rare, with few studies focusing on the metastatic TSCST prognosis. The value of treatments, including radical orchiectomy (RO) and retroperitoneal lymph node dissection (RPLND), in preventing metastasis is controversial. Additionally, metastatic TSCSTs are resistant to chemotherapy. We aimed to assess the effectiveness and safety of immunotherapy in metastatic TSCSTs after first-line chemotherapy.MethodsWe retrospectively screened patients with testicular tumours undergoing testis surgery between January 2005 and January 2019. Patients with TSCSTs who had undergone testis-sparing surgery (TSS) or RO were identified. The malignant type was defined as metastasis confirmed by pathology. Treatment responses, progression-free survival (PFS), overall survival (OS) and safety were analysed.ResultsAmong the 494 testicular tumour patients who received TSS or RO, 11 (2.2%) patients with histologically proven TSCSTs were identified. At the last follow-up, 7 patients survived without tumours, and 4 patients developed metastasis and received first-line cisplatin-based chemotherapy, with 1 of them achieving an objective response. Their PFS times were 1.5, 2.2, 9.0, and 17.0 months, respectively. Two patients received immune checkpoint inhibitors (ICIs) after developing chemotherapy resistance and achieved a partial response up to the last follow-up; one of them experienced Grade 1 adverse events, and the other experienced Grade 2 adverse events during immunotherapy. The median OS time of the 4 patients with metastatic TSCSTs was 32 months.ConclusionsTSCSTs are rare, and most are benign with a good prognosis. ICIs represent a promising option for improving clinical outcomes in metastatic TSCSTs.https://www.frontiersin.org/articles/10.3389/fimmu.2021.720359/fulltesticular sex cord stromal tumoursmetastasisimmunotherapyimmune checkpoint inhibitorsPD-1 inhibitorprognosis |
| spellingShingle | Bingqing Shang Chuanzhen Cao Weixing Jiang Hongzhe Shi Xingang Bi Chengxu Cui Jianzhong Shou Shan Zheng Jin Zhang Aiping Zhou Changling Li Jianhui Ma Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy Frontiers in Immunology testicular sex cord stromal tumours metastasis immunotherapy immune checkpoint inhibitors PD-1 inhibitor prognosis |
| title | Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy |
| title_full | Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy |
| title_fullStr | Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy |
| title_full_unstemmed | Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy |
| title_short | Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy |
| title_sort | promising immunotherapy in metastatic testicular sex cord stromal tumours after first line chemotherapy |
| topic | testicular sex cord stromal tumours metastasis immunotherapy immune checkpoint inhibitors PD-1 inhibitor prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.720359/full |
| work_keys_str_mv | AT bingqingshang promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT chuanzhencao promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT weixingjiang promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT hongzheshi promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT xingangbi promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT chengxucui promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT jianzhongshou promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT shanzheng promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT jinzhang promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT aipingzhou promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT changlingli promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy AT jianhuima promisingimmunotherapyinmetastatictesticularsexcordstromaltumoursafterfirstlinechemotherapy |